Breast cancer is a heterogeneous disease, but 70% of cases are characterized by the presence of hormone receptors for estrogen, progesterone, or both. The first line of treatment for these patients, when presenting with metastatic disease, is endocrine therapy in combination with CDK4/6 inhibitors, but the majority develops resistance to treatment within two years.
